Recent Investment Analysts’ Ratings Updates for CVS Health Corporation (CVS)

CVS Health Corporation (NYSE: CVS) has recently received a number of price target changes and ratings updates:

  • 11/10/2017 – CVS Health Corporation was upgraded by analysts at Needham & Company LLC from a “hold” rating to a “buy” rating. They now have a $79.00 price target on the stock, up previously from $69.02.
  • 11/7/2017 – CVS Health Corporation had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $85.00 price target on the stock, down previously from $90.00.
  • 11/7/2017 – CVS Health Corporation had its price target lowered by analysts at Jefferies Group LLC from $86.00 to $76.00. They now have a “hold” rating on the stock.
  • 11/7/2017 – CVS Health Corporation had its price target lowered by analysts at Loop Capital from $83.00 to $73.00. They now have a “hold” rating on the stock.
  • 11/3/2017 – CVS Health Corporation had its price target lowered by analysts at Citigroup Inc. from $87.00 to $74.00. They now have a “neutral” rating on the stock.
  • 10/31/2017 – CVS Health Corporation was downgraded by analysts at TheStreet from a “b-” rating to a “c+” rating.
  • 10/29/2017 – CVS Health Corporation was given a new $86.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock.
  • 10/27/2017 – CVS Health Corporation had its “hold” rating reaffirmed by analysts at Robert W. Baird. They now have a $77.00 price target on the stock.
  • 10/27/2017 – CVS Health Corporation had its “hold” rating reaffirmed by analysts at Loop Capital.
  • 10/24/2017 – CVS Health Corporation was given a new $90.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 10/18/2017 – CVS Health Corporation was given a new $86.00 price target on by analysts at Jefferies Group LLC. They now have a “hold” rating on the stock.
  • 10/12/2017 – CVS Health Corporation had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
  • 10/12/2017 – CVS Health Corporation was given a new $85.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “buy” rating on the stock.
  • 10/9/2017 – CVS Health Corporation had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $95.00 price target on the stock.
  • 9/19/2017 – CVS Health Corporation is now covered by analysts at Royal Bank Of Canada. They set an “outperform” rating and a $95.00 price target on the stock.

CVS Health Corporation (NYSE:CVS) traded down $1.04 during trading on Wednesday, reaching $70.44. The company’s stock had a trading volume of 5,964,000 shares, compared to its average volume of 6,626,966. The company has a quick ratio of 0.55, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $70,710.00, a P/E ratio of 12.52, a price-to-earnings-growth ratio of 1.23 and a beta of 0.86. CVS Health Corporation has a one year low of $66.45 and a one year high of $84.72.

CVS Health Corporation (NYSE:CVS) last released its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.01. The company had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. CVS Health Corporation had a return on equity of 16.96% and a net margin of 2.77%. CVS Health Corporation’s revenue was up 3.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.64 earnings per share. research analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, November 3rd. Shareholders of record on Tuesday, October 24th were given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 2.84%. The ex-dividend date was Monday, October 23rd. CVS Health Corporation’s payout ratio is 41.32%.

In other news, CFO David M. Denton sold 237,078 shares of CVS Health Corporation stock in a transaction on Monday, September 11th. The stock was sold at an average price of $79.65, for a total value of $18,883,262.70. Following the completion of the sale, the chief financial officer now owns 141,096 shares of the company’s stock, valued at $11,238,296.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Thomas M. Moriarty sold 20,547 shares of CVS Health Corporation stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $81.17, for a total value of $1,667,799.99. Following the completion of the sale, the executive vice president now directly owns 43,178 shares of the company’s stock, valued at approximately $3,504,758.26. The disclosure for this sale can be found here. Insiders have sold 714,125 shares of company stock valued at $58,119,381 in the last three months. 0.61% of the stock is currently owned by company insiders.

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply